Massachusetts Financial Services Co. MA Sells 1,935 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Massachusetts Financial Services Co. MA lessened its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 2.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 64,881 shares of the company’s stock after selling 1,935 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in Kiniksa Pharmaceuticals were worth $1,283,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in KNSA. Geode Capital Management LLC raised its position in shares of Kiniksa Pharmaceuticals by 2.0% during the fourth quarter. Geode Capital Management LLC now owns 492,630 shares of the company’s stock valued at $9,744,000 after buying an additional 9,654 shares during the last quarter. Wellington Management Group LLP grew its stake in Kiniksa Pharmaceuticals by 46.3% during the fourth quarter. Wellington Management Group LLP now owns 69,813 shares of the company’s stock valued at $1,381,000 after acquiring an additional 22,096 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Kiniksa Pharmaceuticals by 138.9% in the 4th quarter. JPMorgan Chase & Co. now owns 477,800 shares of the company’s stock valued at $9,451,000 after acquiring an additional 277,827 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Kiniksa Pharmaceuticals in the 4th quarter worth $158,000. Finally, Teacher Retirement System of Texas boosted its holdings in shares of Kiniksa Pharmaceuticals by 7.1% during the 4th quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company’s stock valued at $215,000 after purchasing an additional 719 shares during the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, COO Eben Tessari sold 14,000 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $19.57, for a total transaction of $273,980.00. Following the transaction, the chief operating officer now directly owns 81,975 shares in the company, valued at approximately $1,604,250.75. This represents a 14.59 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Mark Ragosa sold 36,372 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $22.25, for a total transaction of $809,277.00. Following the completion of the sale, the chief financial officer now directly owns 22,958 shares of the company’s stock, valued at approximately $510,815.50. The trade was a 61.30 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 93,766 shares of company stock valued at $2,011,735 over the last three months. 54.57% of the stock is owned by company insiders.

Kiniksa Pharmaceuticals Trading Down 3.9 %

Shares of NASDAQ KNSA opened at $19.48 on Wednesday. Kiniksa Pharmaceuticals, Ltd. has a 12-month low of $16.56 and a 12-month high of $28.15. The firm’s 50-day moving average price is $20.96 and its 200-day moving average price is $21.74. The stock has a market capitalization of $1.42 billion, a price-to-earnings ratio of -139.13 and a beta of 0.31.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). The company had revenue of $122.50 million for the quarter, compared to analysts’ expectations of $123.42 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company’s revenue for the quarter was up 46.9% on a year-over-year basis. During the same quarter last year, the company earned $0.35 earnings per share. On average, equities analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Analysts Set New Price Targets

KNSA has been the topic of several research reports. Citigroup began coverage on Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They issued a “buy” rating and a $40.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, February 25th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Kiniksa Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $37.17.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.